What you need to know when starting TECVAYLI®

TECVAYLI®, like many medications, comes with the potential for side effects. You should be closely monitored in the hospital for 48 hours after all doses in your step-up dosing schedule.

Understanding potential side effects that may come with TECVAYLI®

TECVAYLI® may cause side effects that are serious, life-threatening, or lead to death, including Cytokine Release Syndrome (CRS) and neurologic problems.
Call your healthcare provider right away if you develop any of the signs or symptoms of CRS or neurologic problems listed below at any time during your treatment with TECVAYLI®.
Signs and symptoms of CRS
Symptoms of neurologic problems
Most common side effects

Cytokine Release Syndrome (CRS)

Signs and symptoms of CRS may include:
Fever (100.4°F or higher)
Feeling anxious
Difficulty breathing
Chills
Dizziness or lightheadedness
Fast heartbeat
Confusion or restlessness
Headache
Increased liver enzymes in your blood

Step-up dosing may help reduce both the chance of getting CRS and the severity of it

TECVAYLI® activates your immune cells to help fight your disease, which can lead to CRS. Your provider will give you pretreatment medications and use step-up dosing to decrease the likelihood and severity of CRS. Pretreatment may also be needed for doses given after a dose delay.

When did patients experience CRS?

Most instances of CRS happened during the first 3 doses
Percentage of people who experienced cytokine release syndrome (CRS) at different stages of TECVAYLI® (teclistamab-cqyv) treatment, graph

Severity of CRS experienced by patients

Severity of CRS experienced by patients, graph
33% of patients experienced recurrent CRS.
Recurrent: Returns or happens again after a period of time.
The median time to CRS occurring was 2 days (with a range of 1 to 6 days) after the most recent dose. The median time that CRS lasted was 2 days (with a range of 1 to 9 days).

Learn more about the TECVAYLI® step-up dosing schedule